The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Incyte Corp (NASDAQ: INCY) closed at $84.76 in the last session, down -0.33% from day before closing price of $85.04. In other words, the price has decreased by -$0.33 from its previous closing price. On the day, 1.64 million shares were traded. INCY stock price reached its highest trading level at $85.87 during the session, while it also had its lowest trading level at $84.43.
Ratios:
We take a closer look at INCY’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.83 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.28. For the most recent quarter (mrq), Quick Ratio is recorded 2.78 and its Current Ratio is at 2.85. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On August 01, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $90. Stifel Upgraded its Hold to Buy on June 16, 2025, while the target price for the stock was maintained at $107.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 15 ’25 when Denton Sheila A. sold 277 shares for $86.81 per share. The transaction valued at 24,046 led to the insider holds 33,200 shares of the business.
SHEILA DENTON bought 277 shares of INCY for $24,046 on Aug 15 ’25. On Aug 13 ’25, another insider, BARRY FLANNELLY, who serves as the Officer of the company, bought 75,963 shares for $82.51 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INCY now has a Market Capitalization of 16551593984 and an Enterprise Value of 14226953216. As of this moment, Incyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.27, and their Forward P/E ratio for the next fiscal year is 11.92. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.19. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.61 while its Price-to-Book (P/B) ratio in mrq is 3.94. Its current Enterprise Value per Revenue stands at 3.103 whereas that against EBITDA is 13.41.
Stock Price History:
The Beta on a monthly basis for INCY is 0.75, which has changed by 0.29148257 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, INCY has reached a high of $87.24, while it has fallen to a 52-week low of $53.56. The 50-Day Moving Average of the stock is 14.74%, while the 200-Day Moving Average is calculated to be 21.82%.
Shares Statistics:
According to the various share statistics, INCY traded on average about 1.86M shares per day over the past 3-months and 1807000 shares per day over the past 10 days. A total of 194.12M shares are outstanding, with a floating share count of 192.94M. Insiders hold about 1.19% of the company’s shares, while institutions hold 102.37% stake in the company. Shares short for INCY as of 1753920000 were 7423372 with a Short Ratio of 4.00, compared to 1751241600 on 7288830. Therefore, it implies a Short% of Shares Outstanding of 7423372 and a Short% of Float of 5.37.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 16.0 analysts currently analyzing and rating the stock of Incyte Corp (INCY).The consensus estimate for the next quarter is $1.81, with high estimates of $2.2 and low estimates of $1.46.
Analysts are recommending an EPS of between $7.1 and $4.84 for the fiscal current year, implying an average EPS of $6.11. EPS for the following year is $7.17, with 20.0 analysts recommending between $9.3 and $3.42.
Revenue Estimates
According to 19 analysts, the current quarter’s revenue is expected to be $1.26B. It ranges from a high estimate of $1.29B to a low estimate of $1.21B. As of the current estimate, Incyte Corp’s year-ago sales were $1.14BFor the next quarter, 19 analysts are estimating revenue of $1.32B. There is a high estimate of $1.41B for the next quarter, whereas the lowest estimate is $1.27B.
A total of 21 analysts have provided revenue estimates for INCY’s current fiscal year. The highest revenue estimate was $4.92B, while the lowest revenue estimate was $4.77B, resulting in an average revenue estimate of $4.84B. In the same quarter a year ago, actual revenue was $4.24BBased on 21 analysts’ estimates, the company’s revenue will be $5.36B in the next fiscal year. The high estimate is $5.65B and the low estimate is $5.12B.
